GENOME & Co

Corporate Presentation

Investor Relations 2025

June, 2025

Genome & Company

Disclaimer

This document has been prepared by Genome & Company (the “Company”) solely for informational purpose in its presentation to institutional and general investors regarding the proposed IPO and is strictly prohibited to be passed on, copied or redistributed. By participating at this presentation, the recipient of information hereby acknowledges and agrees to comply with restrictions mentioned above and such violation is subject to violation of the Financial Investment Services and Capital Markets Act.

All information related to the Company’s business performance and financial performance contained in this document has been prepared in accordance with corporate accounting standards. “Projections” contained in this document have not been subjected to individual verifications. They are predictions of future, not past, events. This document lays out the Company’s anticipated business and financial performance and includes expressions such as “anticipation”, “forecast”, “plan”, and “expectation”. The “forecasted information” referred to above is influenced by future changes in the business environment and by definition contains uncertainties. Due to this inherent uncertainty, actual performance in the future may differ from what is stated or implied in the forecasted information presented in this document.

Neither the Company nor any of its affiliates, advisors or representatives are responsible for any losses incurred in connection with the use of this material (including cases of negligence). This document does not constitute solicitation for the recruitment, sale, or subscription of shares and no part of the document shall constitute an invitation to relevant contracts and arrangements or investment decisions.

All investment decisions related to stock purchase should be made solely on the basis of information provided through Securities and Exchange Report or (Preliminary) prospectus submitted to Financial Services Commission.

Table of Contents

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright ⓒ Genome & Company. All Rights Reserved.

Company Overview

Company Overview

Company Name	Genome & Company, Inc
CEOs	Hong Yooseok Pae Jisoo Park Hansoo
Date of Incorporation	2015.09.24
Paid-in Capital	₩16.4 Billion (As of Mar. 2025)
Total Employees	100 employees (As of Mar. 2025)
Headquarters	50 Changnyong-daero 256beon-gil, Iui-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea
Website	genomecom.co.kr

Business Areas



The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright ⓒ Genome & Company. All Rights Reserved.

Leadership

Hong Yooseok
CEO

Hankuk University of Foreign Studies, B.A.
Wharton School, University of Pennsylvania, MBA

2007~2013	Head of Eli Lilly Korea, Global EMBU Business Development/Strategy Lead
2014~2020	General Manager, GSK Korea; General Manager, GSK Canada; VP, New Epilepsy Product Development, GSK HQ
2021~2023	CEO, D&D Pharmatech
2023.05~	CEO, Genome & Company

Park Hansoo
CTO

Seoul National University, MD
Seoul National University, Ph.D. in Medicine

2009~2013	Senior Researcher, Harvard Medical School
2013~2015	Principal Investigator, The Jackson Laboratory
2016~	Professor, GIST
2015.09~	CTO, Genome & Company

Pae Jisoo
CEO

Seoul National University, MD
Duke University, MBA

1998~2003	Psychiatrist, Seoul National University Hospital
2005~2007	Consultant, Bain & Company
2007~2008	Director, MSD Korea
2015.09~	CEO, Genome & Company

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright ⓒ Genome & Company. All Rights Reserved.

Genome & Company Organization Hierarchy



* Former Hanmi, Samsung, Green Cross Pharmaceutical employees:
Experienced in synthetic research, labs process research, and pharmacological research

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright ⓒ Genome & Company. All Rights Reserved.

Table of Contents

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright ⓒ Genome & Company. All Rights Reserved.

May 2024 Debiopharm Out-Licensing(Debio0633) : Process & Significance

Development Stages	**Target** Discovery & Validation	**Antibody** Discovery	**Linker & Payload** Discovery	Early **Preclinical** Development & CMC	**Clinical** Development & **Commercialization**
Roles	GENOME&CO	GENOME&CO	Debiopharm	GENOME&CO Debiopharm	Debiopharm

Joint Research Initiated Feb 2021

Out-Licensing May 2024

Total Deal Value: $426M
Upfront: $5M

Significance

1 *"First-in-Class ADC" Development*

Research collaboration with the Clear Goal of Developing a "First-in-Class ADC"

2 *"Synergy of Both Companies' Competency"*

- [Genome]
  - **Novel Target Discovery**
  - **Antibody Development**
- [Debiopharm]
  - **Linker/payload**
  - Oncology Drug Clinical Development

3 *Out-Licensing at an **Early Preclinical Stage***

- **Novel Target ADC** with Significant Commercial Potential
- **High Confidence in Joint Research Outcomes and Capabilities**

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright © Genome & Company. All Rights Reserved.

Debiopharm™
WE DEVELOP FOR PATIENTS

Drug Development in
Oncology & Bacterial Infections

2 Registered compounds

Oxaliplatin

Triptorelin

4 Marketed products

ELOXATIN®

DECAPEPTYL®

SALVACYL®

TRIPTODUR®

Oxaliplatin

Colorectal, Pancreatic & Gastric Cancers

- Sanofi (Eloxatin®, >25years)
- Dr. Reddy's Laboratories (Dacotin®, > 20years)
- Yakult (Elplat®, >15years)

Total sales
$ 22 bil

Triptorelin

Prostate, Breast Cancers

- Ipsen (Decapeptyl®, >35years)
- Adium(Decapeptyl®, > 25 years)
- Aché (Neo Decapeptyl®, > 30 years)
- Ferring (Decapeptyl®, > 15 years)
- Dr. Reddy's (Pamorelin®, > 10 years)
- Azurity (Triptodur®, > 8 years)

Total sales
$ 9.5 bil

G&Co

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright © Genome & Company. All Rights Reserved.

GENA-104(EP0089) Out-Licensing: **Significance & Future Prospects**

Development Stages

Target Discovery & Validation → **Antibody** Discovery → **Preclinical** Development & CMC → Phase 1 **IND Approval** → **Clinical** Development & **Commercialization**

Roles

GENOME & Co

ELLIPSES PHARMA

Out-Licensing
Feb 2025

Significance

1 ***Repeated Validation*** *of* ***Novel Target Discovery*** *and* ***Antibody Development*** *Capabilities*

- Proven Track Record in Out-Licensing Preclinical ADC Candidates and Antibodies

2 *Proved* ***Preclinical Development Capabilities*** *for Novel Immuno-Oncology Drugs*

3 ***Maximized*** *Development* ***Success Probability*** *by collaborating with Ellipses' Innovative Business Model*

- Eliminates financial risk
- Leverages Ellipses Pharma's drug development capabilities and know-how.

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright © Genome & Company. All Rights Reserved.

Ellipses Pharma's unique Drug Development Strategy

"Accelerating Development Timelines; Risk-Minimizing Business Model"

Eliminating delays

- Innovative funding model

➔ Uninterrupted drug development

"De-risked Selection of Superior Assets"

De-risking asset selection

- 320 Global key opinion leader group Advisors

"Proven Operational Excellence"

Operational excellence

- Highly experienced team

Traditional model

Ellipses model





The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright © Genome & Company. All Rights Reserved.

GENA-104(EP0089) Licensing Decision: Rationale & Expected Benefits

Timing of Licensing & Clinical Scope



Key Considerations & Expected Outcomes

1. Phase 1 Clinical Development Led by Ellipses Pharma
   → Ellipses Pharma provides **substantial clinical funding** and **world-class clinical expertise**.
2. **Large-scale** Clinical Development with Optimal Design
   → Maximizes clinical success probability.
   → Secures diverse data necessary for large-scale future deals.
3. Securing Revenue Upside through **Maximized Deal Size** after Phase 1
   → All future revenues to be distributed at double-digit %

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright ⓒ Genome & Company. All Rights Reserved.

GENA-104(EP0089) Novel Target Immuno-Oncology L/O: Future Revenue Potential & Reference Deals

GENA-104 (Post-Clinical Development) Potential L/O Deal Case Reference

	iTeos - GSK Co-Development (2021.06)	Innate - AZ/MedImmune Co-Development Option (2015.04)	Arcus - Gilead Option Licensing (2020.05)	MacroGenics - Incyte Licensing (2017.10)	Biond - Sanofi Licensing (2021.01)
Asset	Belrestotug (Anti-TIGIT mAb)	Monalizumab (Anti-NKG2A mAb)	Zimberelimab (Anti-PD-1 mAb) Domvanalimab (Anti-TIGIT mAb) Etrumadenant (A2A/A2B Rec Antagonist) Quemliclustat (CD73 Inhibitor)	Retifanlimab (Anti-PD-1 mAb)	BND-22 (Anti-ILT2 mAb)
Development Stage at Deal Signing	Phase 1	Phase 2	Phase 1 Phase 2	Phase 1	IND Filing
Upfront	$625M	$250M	$175M	$150M	$125M
Milestone	Up to $1,450M	Up to $775M	Up to $1,775M+	Up to $750M	Up to $1,000M
Total Deal Value	Total $2,075M	Total $1,025M	Total $1,950M+	Total $900M	Total $1,125M
Royalties	(Ex-US) Tiered royalties, 최대 20%	(Ex-Europe) Tiered, double-digit royalties	Tiered, double-digit royalties	Tiered royalties (15%~24%)	Tiered, double-digit royalties
Other	(US) 50:50 Profit Share	(EU) 50:50 Profit Share $100M Option Exercise Fee	$200M Equity Investment Agreement Separately Signed	N/A	N/A

CNTN4 Target and potential application as novel ICPi and ADC



Novel Target (CNTN4) Discovery & Antibody Development



- CNTN4 is expressed on tumor cells.
- CNTN4 inhibits T-cell activation through its binding to APP (Binding partner).

GENA-104 – Novel ICPi



- **Anti-CNTN4** (GENA-104) inhibits CNTN4.

→ T-cells are activated

→ Tumor cell elimination/death

ADC (GENA-104 – linker-payload)



- **Anti-CNTN4 – Linker – Payload (ADC)** binds to CNTN4 on the tumor cell surface.

→ Internalization

→ Payload induces tumor cell death

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright ⓒ Genome & Company. All Rights Reserved.

CNTN4 is Highly Expressed Across Various Cancer Types; but Minimally Expressed in Normal Tissues.

GENA-104 → ICPi / ADC

CNTN4 Expression Rate by Cancer Type (IHC Analysis)



*Sample size for each human cancer type – Esophagus 48; GIST 50; Skin 39; Ovary 55; Kidney 50; Lymphoma 10, Cervix 60; H&N 62; Lung 58; Breast 58; Thyroid 49; Sarcoma 57; Colon 52; Bladder 10; Prostate 49; Melanoma 9; Liver 69; Endometrium 10; Stomach 55; Pancreas 10; Gallbladder 10

CNTN4 Expression in Normal Tissues

Body systems	Specific positive tissues (IHC), %
Circulatory	0 %
Digestive	0 %
Endocrine	0 %
Immune	0 %
Integumentary	0 %
Muscular	0 %
Nervous	67 % (2/3)
Reproductive	0 %
Respiratory	0 %
Urinary	0 %
Total 30 tissues examined	6.7% (2/30)

Tissue cross reactivity study results using GENA-104A16

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright © Genome & Company. All Rights Reserved.

Mutually Exclusive Expression Profiles of CNTN4 and PD-L1 in Tumor Tissues

GENA-104 → ICPi / ADC

Heat Map of CNTN4 and PD-L1 Expression Scores (0 ~ +3) through IHC Analysis for Each Cancer Patient



17 TMA slides containing about 900 human tumors; SP142 (Ventana) for PD-L1

An overwhelmingly larger number of patients express **CNTN4** compared to PD-L1, demonstrating a **mutually exclusive expression profile.**

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright © Genome & Company. All Rights Reserved.

High CNTN4 Expression in PD-L1 High Non-Responding Patients

GENA-104 → ICPi / ADC

Analysis of Gastric Cancer Patient Cohort Treated with Anti-PD-1

Overall Response Rate (ORR) of patients subgrouped by median expression levels of CNTN4 and CD274

ORR		*CNTN4* High	*CNTN4* Low
CD274	High	**0%** (0/9)	**64.3%** (9/14)
CD274	Low	**7.1%** (1/14)	**25%** (2/8)

PD-L1 High patients who **express CNTN4 show no response to anti-PD-1.**

Proportions of responders and non-responders within CNTN4–low and –high groups



The majority (95.6%) of **CNTN4 High** patients showed **no response to anti-PD-1.**

Potential Validated in PD-1 Non-Responding Patients

Student's t-test for CNTN4 levels between responders and non-responders, and chi-squared test for CNTN4 levels (high and low according to median value) and responsiveness (responders and non-responders)

Kim, S. T. *et al.* Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. *Nature Medicine 2018 24:9* **24**, 1449–1458 (2018).

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright © Genome & Company. All Rights Reserved.

CNTN4 Expression Affects Survival Rate





In gastric cancer patients treated with anti–PD-1 therapy, **high CNTN4 expression** is associated with **lower overall survival**

Kim, S. T. et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nature Medicine 2018 24:9 24, 1449–1458 (2018).

G&Co

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright ⓒ Genome & Company. All Rights Reserved.

Anti-Tumor Efficacy of GENA-104 Across Animal Models with Varying CNTN4 Expression Levels

GENA-104 → ICPi / ADC

In CNTN4-Expressing CT26 Model



In Low CNTN4-Expressing CT26 Model



In CNTN4-Negative MC38 Model



The data are displayed as means ± SD;
*P < 0.05, ***P < 0.001, ****P < 0.0001 *vs.* control group (hIgG4) by multiple comparison using two-way ANOVA.

With CNTN4 expression➔ 80% tumor growth inhibition

With low CNTN4 expression➔ Reduced tumor growth inhibition

Without CNTN4 expression➔ No efficacy observed

Confirmed: Anti-tumor efficacy improves with higher CNTN4 expression

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright ⓒ Genome & Company. All Rights Reserved.

Expectations for GENA-104

Unmet Needs of PD-(L)1

- Success of PD-(L)1
  - A new paradigm in cancer immunotherapy
  - The most commercially successful drug in history
- Unmet needs of PD-(L)1
  - In many cancers, **only a limited proportion of patients respond** to currently available immunotherapy

Potential of GENA-104

- Key findings from Genome & Company's preclinical studies:
  - Mutually exclusive expression profile between CNTN4 and PD-L1
  - High CNTN4 expression across various tumors
  - Superior preclinical efficacy of GENA-104 as an immuno-oncology drug

- Proof of Concept (PoC) confirmed through strong clinical research capabilities of Ellipses Pharma

Expected Outcome

- If **clinical utility is demonstrated in PD-L1 non-responders**,

1) GENA-104 could help **address major unmet needs** in current immunotherapy
2) It has the potential to achieve **significant commercial success**

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright © Genome & Company. All Rights Reserved.

GNOCLE™: A Genomics-Based Platform for Discovering New Therapeutic Targets



Published paper IF >10 (JCR IF, Year 2023)

The Human Microbiome Project (HMP) is an extension of the Human Genome Project (HGP)

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright © Genome & Company. All Rights Reserved.

Securing Multiple Novel Oncology Targets for ADCs via the GNOCLE™ Platform

As of January 2025

Modality	Pipeline	Target	Developmental Status
			Target / Hit / Lead / Nonclinical candidate / IND enabling / Phase I
ADC	Debio 0633	Hide	2024.05 **License-Out**
	GENA-104	CNTN4	
	GENA-120	N/D	
	GENA-121	N/D	
	GENA-122	N/D	
	ADC Programs	N/D	
mAb (Immuno-oncology)	GENA-104 (EP0089)	CNTN4	Phase I IND Approval **License-Out**
	GENA-119	APP	KDDF 2023~2025 Lead Selection
NCE	GENC-116	N/D	

N/D, not disclosed; mAb, monoclonal antibody; ADC, antibody-drug conjugate; NCE, new chemical entity

Debiopharm

ELLIPSES

Components of ADC and Their Respective Roles

	Monoclonal Antibody	Linker	Payload
Role of the 3 ADC Components	• Binds to antigens specifically expressed in tumor tissue → Delivers the payload to the tumor	• Linking the payload with the antibody	• Kills cancer cells effectively
Desirable Characteristics	• **Selectivity**: High expression in tumor vs. normal tissues • **Internalization**: Efficient internalization post-binding, maximizing cytotoxicity • **Low immunogenicity** (Anti-drug Ab)	• Stable in serum • Effectively releasing the payload in cancer cells	• Favorable efficacy vs. toxicity profile

- Growing need for novel targets

➔ Innovation will become **increasingly** important in the future

- Existing linkers and payloads are mostly patented and commercialized
- Proprietary linker-payload options available (e.g., Lonza, GeneQuantum, Lotte B)
- Big Pharma often internalizes such technologies via M&A

➔ Innovation opportunities may be relatively **limited**

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright © Genome & Company. All Rights Reserved.

Securing Multiple Novel ADC Targets through the GNOCLE™ Platform

As of January 2025

Modality	Pipeline	Target	Developmental Status
			Target / Hit / Lead / Nonclinical candidate / IND enabling / Phase I
ADC	Debio 0633	Hide	2024.05 **License-Out**
	GENA-104	CNTN4	
	GENA-120	N/D	
	GENA-121	N/D	
	GENA-122	N/D	
	ADC Programs	N/D	
mAb (Immuno-oncology)	GENA-104 (EP0089)	CNTN4	Phase I IND Approval **License-Out**
	GENA-119	APP	KDDF 2023~2025 Lead Selection
NCE	GENC-116	N/D	

N/D, not disclosed; mAb, monoclonal antibody; ADC, antibody-drug conjugate; NCE, new chemical entity

Debiopharm

ELLIPSES

CNTN4 is minimally expressed in normal and immune cells, suggesting favorable safety profile



CNTN4 Expression in Normal Tissues

Body systems	Specific positive tissues (IHC), %
Circulatory	0 %
Digestive	0 %
Endocrine	0 %
Immune	0 %
Integumentary	0 %
Muscular	0 %
Nervous	67 % (2/3)
Reproductive	0 %
Respiratory	0 %
Urinary	0 %
Total 30 tissues examined	6.7% (2/30)

Tissue cross reactivity study results using GENA-104A16

CNTN4 Expression in Human Immune Cells (Protein Expression, FACS)

Immune cell	Activation	Population	CNTN4	
			2022-ICPS-06	2022-ICPS-13
T cell	No activation	CD4 T cell	negative	negative
		CD8 T cell	negative	negative
		Treg	negative	negative
	Activation	CD4 T cell	negative	negative
		CD8 T cell	negative	negative
		Treg	negative	negative
Macrophage	Differentiation	M1	negative	negative
		M2	negative	negative
		MoDC	negative	negative
	Maturation	M1	negative	negative
		M2	negative	negative
		MoDC	negative	negative
NK cell	-		negative	negative
B cell	No stimulation		negative	negative
	Stimulation		negative	negative
DC	No activation	pDC	negative	negative
		cDC1	negative	negative
		cDC2	negative	negative
	Activation	pDC	negative	negative
		cDC1	negative	negative
		cDC2	negative	negative

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright ⓒ Genome & Company. All Rights Reserved.

GENA-104A16 antibody shows strong internalization, a key requirement for ADCs, and demonstrated anti-tumor efficacy in preclinical studies



Internalization

Internalization of GENA-104A16



Internalization of GENA-104A16-vc.MMAF



HT1080/CNTN4 Fibrosarcoma CDX Model

DXd & Exatecan (high DARs)



Efficacy of DXd or exatecan (high DAR)-conjugated GENA-104A16-ADCs in a CDX model using CNTN4 overexpressing HT-1080 human fibrosarcoma cell line (HT-1080/CNTN4).

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright © Genome & Company. All Rights Reserved.

Table of Contents

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright ⓒ Genome & Company. All Rights Reserved.

Introduction to the UIQ Brand

UIQ, [ju:ik / 유이크 / 유이끄]

A French-sounding word evoking "beneficial bacteria."

Brand Vision	Skin health-enhancing ‘UIQ' microbiome cosmetics
Brand Concept	Exploring the Origin of Skin Health. Explore the Origin, UIQ
Core Value	Origin I Balance I Awakening

Restoring the microbiome of healthy skin enables anyone to regain skin health



Identifying prevalent **Cutibacterium** species on the **skin of healthy women in their 20s**, and integrating those with **skin barrier reinforcement benefits** into raw materials.

UIQ's Domestic Strategy & Overseas Strategy

Domestic Strategy

Increasing brand awareness

- Securing brand awareness through exclusive model RIIZE and influencers
- Expanding traffic to own online mall
- Discovering Hit One Item for each of the domestic BIG3 channels
- Emphasizing patents and science for brand expertise and differentiated marketing

Strengthening product lines and expanding products

- Reinforcing the brand's signature lines
- Launching new product lines
- Launching the inner beauty brand 'U EAT UIQ'

Overseas Strategy

Expanding distribution networks in Asia and Eastern Europe, leveraging the current presence in 9 countries



United States:

- Entry into B2C platforms such as Amazon
- Establishing bases in the United States and Costa Rica

→ Expansion into South America

Russia:

- Discovering B2B overseas partners (large-scale partners)

→ Expanding into Eastern Europe

Indonesia:

- Entry into Skincara's 1st branch

→ Expansion into Southeast Asia

Japan:

- Entry into duty-free shops, pop-up stores, department stores, and variety shops

By achieving 8 billion won in sales in 2024, we plan to establish ourselves as **a new rising brand**.

Cosmetics Business Growth



2021:

Brand launch

- Launch of UIQ
- Opening of own online store

2022: Expansion of domestic business

- Launch of Kakao Makers
- Launch of Derma Clean Beauty 'Biome Remedy' line
- Contract with model Kang Tae-oh
- Opening of UIQ popup store in Myeongdong

2023: Selection of exclusive model and expansion into overseas markets

- Contract with model RIIZE
- Opening of LOFT popup store in Japan
- Entry into Lotte Duty Free Ginza
- Entry into Japanese department stores (Osaka, Hiroshima).

2024: Diversification of domestic channels and expansion into overseas markets

- Diversification of domestic channels
  - Online: Utilization of own online mall, Big 3 online malls, and YouTuber markets
  - Offline: Entry into new channels (duty-free shops, Olive Young, etc.)
  - Inner beauty: Launch of 'U EAT UIQ'
- Expansion into overseas markets
  - Japan: Official stores opened on Qoo10 and Rakuten, operated directly
  - Global: Exploration of partnerships with local leading distributors in Indonesia and Eastern Europe

Table of Contents

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright ⓒ Genome & Company. All Rights Reserved.

Genome & Company Commercialization Strategy Progress

	2024	2025~2027	2028~
New Target Anti-Cancer Drug Technology Transfer	• Licensing out of new target ADC antibody worth KRW 580 billion to Debiopharm	• Licensing out of new target immunotherapy GENA-104 to Ellipses Pharma • Repeated licensing out of new target ADC or antibodies every 12–18 months	• Greater value licensing out of new target ADCs in clinical stages - Targeting upfront payments over KRW 100 billion
Microbiome Commercial-ization	• UIQ Cosmetics - 2024 sales forecast: KRW 8 billion (400% YoY growth) - Launching in Olive Young - Full-scale entry into Japanese market	• UIQ Cosmetics - Achieve KRW 70 billion in sales - Enter Japanese market as K-beauty front-runner - Expand to Amazon US distribution and begin full-scale commercialization	• UIQ Cosmetics - Achieve over KRW 150 billion in sales - Target 60%+ overseas sales share (centered on Japan and the US)
	• Probiotics Health Supplements - US: Partner selection for raw materials/finished products in progress - Korea: Launch of 3 pilot-type probiotic products	• Probiotics Health Supplements - US: 3–5 strains to be registered as GRAS raw materials - Sales of finished/raw materials to reach KRW 50 billion	• Probiotics Health Supplements Sales target: KRW 100 billion - US: KRW 50 billion - Korea: KRW 50 billion

Genome & Company Strategy

Phase1 :
- Achieve 2 L/O deals for new-target anti-cancer drugs
- UIQ cosmetics sales expected to reach KRW 8 billion

Phase2 :
- Focus on discovering novel ADC targets
- Start full-scale revenue generation from microbiome commercialization

Phase3 :
- Achieve major ADC deal with in-house Linker-Payload and establish stable revenue model for microbiome commercialization



Microbiome Drug Development Company

A company capable of sustainable growth **through ADC drug development and microbiome commercialization**

The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is not to be shared with any 3rd party or copied to other file without Genome and Company's prior written consent.
Copyright ⓒ Genome & Company. All Rights Reserved.

Genome & Company Financial Plan

Microbiome CDMO Business

list labs

- In 2021, acquired 60% stake in List Labs for $27M
- Currently holding $6M in cash

list bio

- In 2022, raised $48.4M from domestic investors to expand CAPA
- Currently holding $40M in cash

New Drug Development and Commercialization of Microbiome-Based Therapies

R&D

- Achieved two out-licensing (L/O) deals for novel targeted anti-cancer drugs
- Transferred repetitive-use antibody technology for novel target ADCs (Antibody-Drug Conjugates)

Cosmetics (UIQ) Business

- Expected sales of KRW 8 billion in 2024
- Targeting KRW 150 billion in sales and 20% operating margin within 5 years

Health Functional Foods Business

- Targeting KRW 100 billion in sales and 20% operating margin within 5 years

By leveraging the assets and capital of our U.S. subsidiary, we aim to become a self-sustaining, growth-driven company within five years—without relying on external funding.

GENOME & Co

Thank you

Genome & Company (gnc-ir@genomecom.co.kr)